Glenmark Pharmaceuticals receives ANDA approval for HAILEY 1.5/30 and HAILEY Fe 1.5/30
Newsroom
Glenmark’s consolidated revenue at Rs. 22,798.16 Mn. for Q4 FY 2017 – 18
29 May 2018 | Read More
Glenmark Pharmaceuticals Announces Poster Presentations on GBR 1302 and GBR 1342, HER2xCD3 and CD38xCD3 Bispecific Antibodies, at the 2018 ASCO Annual Meeting
28 May 2018 | Read More
Glenmark Pharmaceuticals Announces the Company’s First New Drug Application Submission for RyaltrisTM for Patients with Seasonal Allergic Rhinitis
22 May 2018 | Read More
Glenmark Pharmaceuticals receives ANDA approval for Colesevelam Hydrochloride Tablets, 625 mg
21 May 2018 | Read More
Glenmark Pharmaceuticals Announces Oral Presentation of New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the International Investigative Dermatology Meeting
18 May 2018 | Read More
Glenmark announces grant of substitution and successful launch of generic Seretide® Accuhaler® in Denmark
16 May 2018 | Read More
New and Updated Data on Glenmark Pharmaceuticals GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis, Including an Oral Presentation, to be Presented at the International Investigative Dermatology Meeting
10 May 2018 | Read More
Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Topical Solution USP, 0.05%
20 Apr 2018 | Read More
Glenmark receives ANDA approval for Tacrolimus Ointment, 0.1%
18 Apr 2018 | Read More
Glenmark Pharmaceuticals Announces Initiation of a Phase 2b Trial of GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis
17 Apr 2018 | Read More
Glenmark Pharmaceuticals and Helsinn Group enter into an exclusive licensing agreement for launch of AKYNZEO® in India and Nepal
4 Apr 2018 | Read More
Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Spray, 0.05%
27 Mar 2018 | Read More
Glenmark Pharmaceuticals Presents New Data on Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis at the AAAAI/WAO Joint Congress
6 Mar 2018 | Read More
Glenmark launches a globally-renowned hair growth formula Nourkrin® Woman in India
28 Feb 2018 | Read More
Glenmark Pharmaceuticals Enters Exclusive Collaboration Agreement with SCD Pharmaceuticals, South Korea, for Ophthalmic Solution Products
22 Feb 2018 | Read More
Glenmark Presents New Data on GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting
19 Feb 2018 | Read More
Glenmark’s consolidated revenue at Rs. 22,036.62 Mn for Q3 FY 2017 – 18
9 Feb 2018 | Read More
Glenmark presents Preliminary Biomarker Data on GBR 1302, a HER2xCD3 Bispecific Monoclonal Antibody, at the ASCO-SITC Clinical Immuno-Oncology Symposium
25 Jan 2018 | Read More
Glenmark initiates Phase IIb dose range finding study for novel molecule GRC 27864
15 Jan 2018 | Read More
Glenmark launches the biosimilar of Adalimumab in India
4 Jan 2018 | Read More
Library
Profile – Chairman and Managing Director
With the idea of creating something unique, Glenn Saldanha took over the reins of the company and helped transform it into a global enterprise worth USD 1.4 billion with offices across 40 countries. Download Profile
Profile – Glenmark Pharmaceuticals
Research-driven, global and integrated pharmaceutical company which is driven to meet unmet medical needs and help pave a new way for a new world. Download Profile
For any media related queries, please email corpcomm@glenmarkpharma.com